NASDAQ:BWAY BrainsWay (BWAY) Stock Price, News & Analysis $7.38 +0.23 (+3.22%) (As of 09/9/2024 ET) Add Compare Share Share Today's Range$7.09▼$7.6750-Day Range$5.80▼$8.0552-Week Range$3.09▼$8.28Volume71,493 shsAverage Volume95,061 shsMarket Capitalization$123.10 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get BrainsWay alerts: Email Address BrainsWay MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside71.6% Upside$12.67 Price TargetShort InterestHealthy0.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth116.67%From $0.06 to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 starsMedical Sector236th out of 899 stocksSurgical & Medical Instruments Industry31st out of 94 stocks 3.4 Analyst's Opinion Consensus RatingBrainsWay has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBrainsWay has only been the subject of 2 research reports in the past 90 days.Read more about BrainsWay's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.23% of the outstanding shares of BrainsWay have been sold short.Short Interest Ratio / Days to CoverBrainsWay has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BrainsWay has recently decreased by 8.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainsWay does not currently pay a dividend.Dividend GrowthBrainsWay does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BWAY. Previous Next 3.2 News and Social Media Coverage News SentimentBrainsWay has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BrainsWay this week, compared to 1 article on an average week.Search Interest12 people have searched for BWAY on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BrainsWay insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.11% of the stock of BrainsWay is held by institutions.Read more about BrainsWay's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BrainsWay are expected to grow by 116.67% in the coming year, from $0.06 to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BrainsWay is -81.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BrainsWay is -81.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBrainsWay has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BrainsWay's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingKamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every American’s freedom and financial security.Get the inside scoop and learn how to protect your savings. About BrainsWay Stock (NASDAQ:BWAY)BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Read More BWAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BWAY Stock News HeadlinesAugust 29, 2024 | globenewswire.comBrainsWay Appoints Richard A. Bermudes, M.D.August 27, 2024 | finance.yahoo.comThe Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWaySeptember 10, 2024 | Banyan Hill Publishing (Ad)Kamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every American’s freedom and financial security.August 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Brainsway: Strong Financials and Strategic Growth DriversAugust 7, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Brainsway (BWAY) and G1 Therapeutics (GTHX)August 7, 2024 | msn.comBrainsway beats Q2 estimates, raises guidanceAugust 7, 2024 | seekingalpha.comBrainsWay Ltd. (BWAY) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | globenewswire.comBrainsWay Reports Second Quarter 2024 Financial Results and Operational HighlightsSeptember 10, 2024 | Banyan Hill Publishing (Ad)Kamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every American’s freedom and financial security.July 23, 2024 | globenewswire.comBrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024June 17, 2024 | globenewswire.comBrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in CanadaJune 11, 2024 | investorplace.comSmall-Cap Standouts: 3 Stocks Destined to Rule Their IndustriesJune 11, 2024 | investorplace.comSmall-Cap Standouts: 3 Stocks Destined to Rule Their IndustriesJune 10, 2024 | globenewswire.comBrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for DepressionJune 3, 2024 | globenewswire.comBrainsWay Receives Expanded FDA Labeling to Treat Late Life DepressionMay 9, 2024 | seekingalpha.comBrainsWay: Cash Flows Are UnderappreciatedMay 8, 2024 | markets.businessinsider.comBWAY Stock Earnings: BrainsWay Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comBrainsWay Reports First Quarter 2024 Financial Results and Operational HighlightsSee More Headlines Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/09/2024Next Earnings (Estimated)11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:BWAY CUSIPN/A CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$16.00 Low Stock Price Target$11.00 Potential Upside/Downside+71.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E Ratio123.00 P/E GrowthN/ANet Income$-4,200,000.00 Net Margins1.67% Pretax Margin2.14% Return on Equity1.45% Return on Assets0.96% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio4.39 Sales & Book Value Annual Sales$31.78 million Price / Sales3.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book2.95Miscellaneous Outstanding Shares16,680,000Free Float13,499,000Market Cap$123.10 million OptionableNot Optionable Beta1.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Hadar Levy (Age 50)Chief Executive Officer Comp: $434kMr. Avner Hagai (Age 68)Founder & Director Comp: $43.65kProf. Abraham Zangen (Age 54)Co-Founder, Member of Scientific Advisory Board & Director Comp: $72.17kDr. Yiftach Roth Ph.D. (Age 53)Founder & Chief Scientific Officer Comp: $108kMr. Ido Marom (Age 48)Chief Financial Officer Mr. Menachem C. Klein Esq.VP, General Counsel & Corporate SecretaryDr. Aron TendlerChief Medical OfficerMore ExecutivesKey CompetitorsBeyond AirNASDAQ:XAIRZimVieNASDAQ:ZIMVJin Medical InternationalNASDAQ:ZJYLTreace Medical ConceptsNASDAQ:TMCINano-X ImagingNASDAQ:NNOXView All CompetitorsInstitutional OwnershipMarshall Wace LLPSold 62,983 shares on 8/14/2024Ownership: 0.510%Cubist Systematic Strategies LLCSold 2,059 shares on 8/14/2024Ownership: 0.072%Perritt Capital Management IncBought 20,000 shares on 8/8/2024Ownership: 0.120%Acadian Asset Management LLCBought 84,371 shares on 8/6/2024Ownership: 1.558%Rhumbline AdvisersBought 1,695 shares on 8/1/2024Ownership: 0.108%View All Institutional Transactions BWAY Stock Analysis - Frequently Asked Questions How have BWAY shares performed this year? BrainsWay's stock was trading at $6.48 at the beginning of 2024. Since then, BWAY shares have increased by 13.9% and is now trading at $7.38. View the best growth stocks for 2024 here. How were BrainsWay's earnings last quarter? BrainsWay Ltd. (NASDAQ:BWAY) released its earnings results on Tuesday, August, 6th. The company reported $0.04 earnings per share (EPS) for the quarter. The company earned $10.01 million during the quarter, compared to analysts' expectations of $9.40 million. BrainsWay had a net margin of 1.67% and a trailing twelve-month return on equity of 1.45%. When did BrainsWay IPO? BrainsWay (BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO. Who are BrainsWay's major shareholders? Top institutional shareholders of BrainsWay include Acadian Asset Management LLC (1.56%), Marshall Wace LLP (0.51%), Perritt Capital Management Inc (0.12%) and Rhumbline Advisers (0.11%). How do I buy shares of BrainsWay? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BrainsWay own? Based on aggregate information from My MarketBeat watchlists, some other companies that BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI) and This page (NASDAQ:BWAY) was last updated on 9/10/2024 by MarketBeat.com Staff From Our PartnersYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BrainsWay With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BWAY Stock Alerts